Search
News
NOG Q2 2026 Earnings: Gas Growth Offset Lower Oil Volumes
Northern Oil and Gas (NOG) reported Q2 2026 oil and gas sales of $670.8 million, about 17% above the prior year, and GAAP diluted EPS of $2.19 versus $1.00. Total production rose 9% to 145,659 Boe per day as natural gas output increased 35%, offsetting an 11% oil decline caused partly by Permian shut-ins and delayed turn-in-lines. Free cash flow reached $159.0 million, up 26% year over year, while NOG maintained its full-year production and capital-spending guidance and improved several cost and price-differential assumptions.
TradingKey
Thu, Aug 6
Octave Q2 2026 Earnings: Distribution Growth Narrows Losses
Octave Specialty Group’s Q2 2026 revenue rose 51% to $83.0 million, while diluted loss per share from continuing operations narrowed to $0.33 from $0.42. Adjusted EBITDA attributable to shareholders improved to $3.7 million from a $4.6 million loss, led by 77% revenue growth in Insurance Distribution and better Everspan underwriting results. However, a $14.4 million GAAP loss attributable to shareholders, corporate costs, and a 100.6% Everspan combined ratio show that consolidated profitability remains the central issue despite meaningful operating improvement.
TradingKey
Thu, Aug 6
Ouster Q2 2026 earnings: Revenue rises 56% as gross margin reaches 49%
Ouster’s Q2 2026 revenue rose 56% year over year to $54.6 million, while GAAP gross margin expanded 400 basis points to 49%. The lidar and camera sensor company reduced its GAAP net loss to $18.1 million, or $0.27 per share, and narrowed adjusted EBITDA loss to $4.5 million. More than 17,000 sensors shipped, led by demand from industrial and smart infrastructure customers. Ouster guided Q3 revenue to $54.5 million–$57.5 million, while first-half operating cash use increased to $20.0 million despite improved profitability.
TradingKey
Thu, Aug 6
Granite Ridge Q2 2026 earnings: Higher oil prices lift sales as costs rise
Granite Ridge Resources’ Q2 2026 oil and natural gas sales rose 36.7% to $149.3 million, while diluted EPS increased to $0.23 from $0.19. Net income reached $30.0 million and adjusted EBITDAX rose 5.6% to $79.6 million, but production increased only 1% and lease operating expense climbed 47% per Boe to $10.27. Operating cash flow of $55.6 million remained below $95.2 million of quarterly capital spending as the company continued investing toward a targeted 2027 free-cash-flow inflection.
TradingKey
Thu, Aug 6
AEye Q2 2026 Earnings: Revenue Grows Ninefold but Net Loss Widens
AEye’s Q2 2026 revenue rose to $202,000 from $22,000 a year earlier, while its GAAP net loss widened to $10.0 million. Loss per share narrowed to $0.22 from $0.48 because the weighted-average share count more than doubled, not because the company became profitable. Quarterly cash consumption was $7.5 million, and cash plus marketable securities totaled $71.5 million. Commercial activity reached records, but revenue remains small relative to operating costs.
TradingKey
Thu, Aug 6
Instacart Q2 2026 Earnings: Revenue Rises 14% as Free Cash Flow Accelerates
Instacart (NASDAQ: CART) reported Q2 2026 revenue of $1.043 billion, up 14% year over year, while diluted EPS increased to $0.45 from $0.41. GTV rose 14% to $10.351 billion, adjusted EBITDA advanced 19% to $313 million, and free cash flow reached $480 million. GAAP net income nevertheless declined 4% to $111 million as gross margin narrowed to 72% and higher taxes and lower interest income offset operating-profit growth. Q3 guidance calls for GTV of $10.3-$10.55 billion and adjusted EBITDA of $320-$340 million.
TradingKey
Thu, Aug 6
Willdan Q2 FY2026 earnings: Energy demand drives 23.5% net revenue growth
Willdan (NASDAQ: WLDN) reported Q2 fiscal 2026 contract revenue of $231.0 million, up 33.2%, while non-GAAP net revenue rose 23.5% to $117.2 million. GAAP diluted EPS increased 53.4% to $1.58, and adjusted EBITDA grew 50.6% to $33.0 million as energy demand, favorable mix and operating leverage supported profitability. The Energy segment drove most of the growth, while first-half operating cash flow declined as receivables and contract assets absorbed cash. Willdan also raised its FY2026 targets, including net revenue of $415 million to $430 million.
TradingKey
Thu, Aug 6
BRC Group Q2 2026 earnings: Wealth Management lifts revenue as net income falls
BRC Group Holdings (Nasdaq: RILY) reported Q2 2026 revenue of $239.1 million, up about 6.1% year over year, while diluted EPS fell to $0.45 from $4.50. Net income available to common shareholders was $18.5 million, compared with $137.5 million, largely because the prior-year quarter included discontinued-operations income and a senior-note exchange gain. Operating Adjusted EBITDA rose to $66.0 million from $43.3 million, supported by Wealth Management and lower operating expenses. Net debt declined to $285.2 million at June 30, primarily due to investment appreciation.
TradingKey
Thu, Aug 6
Halozyme Q2 2026 results: Royalty revenue rises 50% as guidance increases
Halozyme’s Q2 2026 revenue rose 48% year over year to $481.0 million, led by a 50% increase in royalty revenue to $307.7 million. GAAP diluted EPS increased to $1.90 from $1.33, while non-GAAP diluted EPS reached $2.28 and adjusted EBITDA rose 46% to $328.8 million. Operating margin narrowed as product costs, acquisition-related amortization and R&D increased. Halozyme also raised its full-year 2026 revenue, royalty revenue, adjusted EBITDA and non-GAAP EPS guidance, supported by partner-product uptake and higher product sales.
TradingKey
Thu, Aug 6
10x Genomics Q2 2026 earnings: Revenue excluding settlements grew 3%
10x Genomics reported Q2 2026 revenue of $151.0 million, down from $172.9 million, and diluted EPS of -$0.14 versus $0.28 a year earlier. Excluding patent-settlement license and royalty revenue in both periods, revenue grew 3%, while gross margin improved to 74% from 72% on lower manufacturing costs, tariff refunds and lower inventory write-downs. Cash and marketable securities totaled $552.0 million at quarter-end. The company raised full-year 2026 revenue guidance to $610 million-$630 million as consumables and services growth offset weaker instrument revenue and lower settlement benefits.
TradingKey
Thu, Aug 6
BioLife Q2 2026 Earnings: Revenue Rises 21% as Operating Profit Turns Positive
BioLife Solutions’ Q2 2026 revenue rose 21% to $28.5 million, while GAAP operating income turned positive at $1.7 million from a $16.1 million loss. Adjusted EBITDA increased to $7.4 million, or 26% of revenue. GAAP net income reached $45.1 million, but included a $42.4 million noncash tax benefit, making adjusted net income of $4.2 million a clearer measure of operating progress. The quarter also precedes Repligen’s proposed $1.5 billion acquisition, expected to close in Q4 2026 subject to approvals.
TradingKey
Thu, Aug 6
BioMarin Q2 2026 Earnings: Revenue Rises 20% as Acquisition Costs Weigh on Profit
BioMarin’s Q2 2026 revenue rose 20% year over year to $990 million, while GAAP diluted EPS fell to $0.23 from $1.23 and non-GAAP diluted EPS declined 17% to $1.20. GALAFOLD and POMBILITI + OPFOLDA, added through the April 27 Amicus acquisition, and continued VOXZOGO and PALYNZIQ growth lifted sales, but acquisition, financing, marketing, and R&D costs pressured earnings. BioMarin raised full-year revenue guidance to $3.875-$3.925 billion and non-GAAP EPS guidance to $4.90-$5.10.
TradingKey
Thu, Aug 6
Astrana Health Q2 2026 earnings: Revenue rises 49% as diluted EPS more than doubles
Astrana Health’s Q2 2026 revenue rose 49% year over year to $972.5 million, while diluted GAAP EPS increased to $0.40 from $0.19. Net income attributable to Astrana more than doubled to $19.7 million, and adjusted EBITDA advanced 43% to $68.9 million with a 7% margin. Growth was broad across Care Partners, Care Delivery, and Care Enablement, though Care Partners operating income declined 14%. The company raised full-year 2026 adjusted EBITDA guidance to $255 million-$280 million while reaffirming its revenue and free cash flow ranges.
TradingKey
Thu, Aug 6
Aflac Q2 2026 Earnings: Lower Investment Losses Lift GAAP Profit as Adjusted Earnings Fall
Aflac’s Q2 2026 revenue declined 1.0% to $4.117 billion, while GAAP diluted EPS rose to $1.63 from $1.11 as net investment losses narrowed sharply. Adjusted earnings fell 7.7% to $883 million, although adjusted EPS decreased only 1.7% to $1.75 and increased 1.1% excluding current-period currency effects. Japan’s yen-based margin improved on favorable benefits, while higher U.S. benefits reduced segment profit. The weaker yen, lower investment income and a Corporate and Other loss remained key pressures as Aflac returned $1.3 billion to shareholders.
TradingKey
Thu, Aug 6
Artivion Q2 2026 Earnings: Revenue Growth Came With a GAAP Loss
Artivion’s Q2 2026 revenue rose 11% to $125.8 million, led by On-X and aortic stent grafts, while diluted EPS moved to a $0.28 loss from $0.03 of profit. Adjusted EBITDA increased 7% to $26.4 million, but adjusted net income fell to $6.3 million and free cash flow was negative $12.0 million. Artivion reiterated full-year revenue guidance of $480 million to $496 million and adjusted EBITDA guidance of $92 million to $99 million following the Endospan acquisition and FDA approval of AMDS.
TradingKey
Thu, Aug 6
Gen Digital Q1 FY2027 earnings: Trust-Based Solutions drives 6% revenue growth
Gen Digital’s Q1 FY2027 revenue increased 6% to $1.336 billion, GAAP diluted EPS rose 65% to $0.36, and free cash flow reached $430 million. Trust-Based Solutions revenue climbed to $490 million, offsetting a reported decline in Cyber Safety Platform revenue, while GAAP operating margin narrowed to 33.2%. On a comparable adjusted basis, revenue grew 11%. Gen raised full-year non-GAAP revenue guidance to $5.375 billion-$5.475 billion and EPS guidance to $2.87-$2.97, leaving margins and Cyber Safety trends as key follow-up areas.
TradingKey
Thu, Aug 6
PRA Group Q2 2026 Earnings: European ERC Review Lifts Revenue and Profit
PRA Group’s Q2 2026 revenue increased 29% year over year to $372.2 million, while GAAP diluted EPS rose to $1.51 from $1.08. Total cash collections grew 4% to $558.5 million, a much slower pace than reported revenue, because a comprehensive European portfolio review increased ERC by approximately $349 million and lifted changes in expected recoveries. Operating expenses rose 8% to $218.9 million, mainly due to higher legal collection costs, while net income attributable to PRA Group reached $57.9 million. Investors should monitor whether revised European recovery forecasts convert into sustained collections.
TradingKey
Thu, Aug 6
Rocket Companies Q2 2026 earnings: Revenue nearly doubles as mortgage profitability expands
Rocket Companies (NYSE: RKT) reported Q2 2026 net revenue of $2.78 billion, up from $1.45 billion a year earlier, while GAAP diluted EPS improved to $0.08 from a $0.01 loss. Adjusted EBITDA rose to $766 million, and Mortgage contribution margin reached $1.17 billion as purchase and refinance market share hit record quarterly levels. Total liquidity stood at $11.2 billion after $53 billion of MSR sales generated $795 million in cash proceeds. Rocket guided Q3 adjusted revenue to $2.5 billion-$2.7 billion, below Q2’s level.
TradingKey
Thu, Aug 6
Lionsgate Fiscal Q1 2027 Earnings: Motion Picture Revenue More Than Doubles
Lionsgate Studios’ fiscal Q1 2027 revenue rose 48% year over year to $776.6 million, while diluted loss per share from continuing operations improved to $0.10 from $0.35. Motion Picture revenue more than doubled to $587.3 million and segment profit reached $105.0 million, offsetting lower Television Production results. Operating cash flow from continuing operations turned positive at $54.1 million, and adjusted free cash flow was $128.9 million. The quarter still ended with a $28.8 million attributable continuing-operations net loss as interest expense and elevated share-based compensation weighed on GAAP results.
TradingKey
Thu, Aug 6
Shoulder Innovations Q2 2026 earnings: 56% revenue growth lifts the outlook
Shoulder Innovations (NYSE: SI) reported Q2 2026 revenue of $17.2 million, up 56%, as implant system volume increased about 50% and average selling price rose 5% to $7,674. Gross margin improved to 78.3% from 76.2%, but operating loss widened to $10.0 million as SG&A and R&D spending increased. The company raised full-year 2026 revenue guidance to $67 million-$69 million, while cash and marketable securities totaled $99.0 million. Investors now need to assess whether commercial expansion can produce better operating leverage.
TradingKey
Thu, Aug 6
Featured Tools
Top News
Oracle Stock Forecast: $630 Billion AI Order Backlog Awaits Revaluation, Can the Stock Continue to Recover?
The Week Ahead: Fed Minutes, Walmart, Target and Home Depot Earnings to Test US Consumer Resilience
New CEO Ternus Launches iPhone 18 Pro on September 9 — Can Apple Reverse Q3 China Miss Before Jackson Hole?
SK Hynix Stock Forecast: Can HBM4 Demand Drive a Breakout Toward $194?
Broadcom Stock Price Forecast: Can It Break $500 Before Earnings Amid Strong Custom AI Chip Demand?
